We announced our financial results for the first three months of 2023.
Q1 Earnings conference call webcast
London
conference call - 9 May 2023
London conference call webcast
The Q3 2023 financial results release will be published in a company announcement at 07.30 CET.
Full-year 2023 financial results will be published in 2024.
Learn more about this year's Annual General Meeting here
R&D investor call in relation to ADA 2023
Novo
Nordisk A/S hosted a R&D investor call in relation to the annual
ADA conference. This year the conference is hosted in San Diego, CA.
Capital Markets Day
03 March 2022
Watch the presentations and get the slides from the Novo Nordisk Capital Markets Day
Annual General Meeting
24 March 2022
Annual General Meeting (webcast)
See previous AGM documentation
5 June: Investor event (ADA 82nd Scientific Sessions)
Presentation (Webcast)
Presentation (pdf)
20 December: Conference call on supply situation for Wegovy®
28 June: R&D investor call
07 June: Approval of Wegovy™ in the US
21 May: International Operations call
25 March: Annual General Meeting
16 December: Decision to enter phase 3 development in Alzheimer’s disease and GLP-1 R&D strategy update
30 November: ESG conference call
9 October: Novo Nordisk raises sales and operating profit
outlook for 2020
19 June: R&D investor presentation
26 March: Annual General Meeting
Stay informed
Stay informed
Be the first one to read our company announcements and press releases. Sign up to Novo Nordisk News.
Investors
Share price
{{priceData.date}} {{priceData.time}}